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The erythropoietin analogs have been an important advance
for the treatment of the anemia of kidney disease, resulting
in reduced need for blood transfusion and improved quality
of life. Recent studies, however, have indicated risks
associated with targeting higher levels of hemoglobin (Hb).
As a result, in March 2007, the US Food and Drug
Administration (FDA) substantially changed prescribing
information for these drugs to alert clinicians to these risks.
In this review, we consider the recent literature, the change
in FDA warnings, and new National Kidney Foundation
Anemia Guidelines. Suggestions for new Hb targets during
erythropoiesis-stimulating agent treatment are presented.
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The availability of erythropoietin analogs (the current
preferred terminology is erythropoiesis-stimulating agents
or ESAs) has been one of the most important medical
advances in the treatment of patients with kidney disease.
Before the availability of ESAs, severe anemia was common
in uremic individuals,1 resulting in disabling fatigue,
substantially diminished quality of life, and the need for
frequent blood transfusions. Partial correction of anemia
with ESA treatment results in reduced need for blood
transfusions, and significantly improved functional health
and well being.2,3
The accumulated experience with the use of ESAs in end-
stage renal disease, non-dialysis chronic kidney disease
(CKD), and other anemic states spans over two decades. As
the use of these agents has expanded and matured, interest in
optimization of therapy has intensified. In recent years, much
of this interest has centered on the extent of hemoglobin
(Hb) correction, in particular, the magnitude of Hb
correction required to achieve the greatest improvement in
outcomes and quality of life.
After Food and Drug Administration (FDA) approval of
epoetin alfa in 1989, the goal for treatment of anemia in
kidney disease was generally to increase Hb to greater than
10 g/dl. This was consistent with FDA labeling, which
specified a target range of 10–12 g/dl. It should be noted that
this labeling was based on safety concerns by the FDA, as the
registration trials with epoetin alfa targeted a hematocrit of
32–38% and achieved an average hematocrit of 36.5%. The
lower limit treatment goal of 10 g/dl remained the usual
practice until publication of the National Kidney Foundation’s
Dialysis Outcomes Quality Initiative (NKF-KDOQI) Anemia
Guidelines in 1997, which recommended an Hb target range
of 11–12 g/dl.4 Between 1991 and 2005, the mean Hb of US
hemodialysis patients increased from 9.7 to 12 g/dl.5 In 2006,
the KDOQI guidelines were updated, recommending main-
taining Hb411 g/dl while noting a lack of evidence for ESA
treatment to target Hb413 g/dl.6 These statements were
misinterpreted by many as a recommendation to increase the
target range to 11–13 g/dl. Similarly, in 2005–2006, the
Centers for Medicare and Medicaid Services modified its
reimbursement policies for ESAs, requiring a dose reduction
only when Hb was greater than 13 g/dl in order to avoid a
post-payment audit of claims. These events appeared to set
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the stage for a new era of higher targets for Hb during ESA
therapy.
A major tipping point in the history of ESA therapy took
place in November 2006. The pivotal event was the
publication of two key studies, correction of hemoglobin
and outcomes in renal insufficiency (CHOIR) and cardio-
vascular risk reduction by early anemia treatment with
epoetin beta (CREATE), both of which indicated a trend
toward an increased risk of death with targeting of higher Hb
concentrations7,8 (these studies are often incorrectly referred
to as the first studies to demonstrate possible harm). In fact,
Besarab et al. in a study in hemodialysis reported very similar
findings 8 years earlier (see below). This was followed, in
early 2007, by reports from two studies conducted in patients
with cancer that indicated safety concerns associated with
ESA treatment in this population (http://www.healthsentinel.
com/news.php?id=1740&title=Studies+Show+Anemia+Drugs+
May+Harm+Cancer+Patients&event=news_print_list_item).
Subsequently, on 9 March 2007, the US FDA drastically
changed labeling for ESAs. The agency inserted a boxed
warning, stating that providers should avoid Hb targets
greater than 12 g/dl because of increased risk of death and
serious cardiac events. In addition, the labeling noted that
ESAs should be used to increase Hb only to the lowest level
necessary to avoid transfusion. These recommendations
created considerable confusion and concern within the
provider and patient communities regarding the available
data and the most effective and safe Hb levels for individual
patients.
The purpose of this paper is to review the recent literature
and consider the application of current scientific knowledge
to clinical guidelines for target Hb. We will focus on the two
major outcomes most clearly associated with ESA therapy,
quality of life and mortality risk.
PROBLEMS WITH CLINICAL GUIDELINES FOR TARGET Hb
The US Agency for Healthcare Research and Quality defines
a treatment practice guideline as ‘a guideline that recom-
mends procedures or practices that are intended to relieve
physical or mental illness or injury.9’ Such guidelines are
not intended to define standards of care, but rather
to be tools to assist clinicians and patients make the best
decisions in individual cases. The need for practice guidelines
derives from a number of factors. First, medical knowledge
often progresses rapidly, exceeding the ability of busy
practicing clinicians to keep pace. Second, the sheer number
of new medical publications is daunting, and no clinician can
hope to read even a small percentage of relevant, published
studies. Third, the process of synthesizing medical literature
while weighing the relative interaction of benefit and risk
requires a broad knowledge of the literature, the relevant
medical science and related health systems. It is highly
sensible to use multidisciplinary panels of experts, with broad
knowledge of a specific medical problem, to review the
literature and use it to design specific guideline statements
for clinical practice.
The process of development of practice guidelines for
binary treatment decisions is simpler than that for decisions
involving continuous variables such as target Hb. It should be
clear that no treatment decision is fully binary. However,
many, such as whether or not to use warfarin to prevent
stroke in atrial fibrillation or aspirin after myocardial
infarction or angiotensin converting enzyme inhibitors in
diabetic kidney disease are to a great extent simple,
dichotomous decisions. For treatment decisions of this type,
it is relatively straightforward to use the literature to develop
practice guidelines. Published studies generally indicate with
reasonable clarity whether the treatment works and is safe.
For a continuous variable like target Hb, translating the
literature into practice guidelines can be very difficult. As an
example of why this is true, we will consider the CHOIR
study. In this trial, patients were randomized to Hb targets of
11.3 and 13.5 g/dl. The primary results were that for the
group randomized to the higher Hb target there was
increased risk as measured by a composite end point. Taken
in isolation, the study indicates that an 11.3 g/dl Hb target is
preferred to a 13.5 g/dl target.7 However, in no way do the
results demonstrate that an 11.3 g/dl Hb target would be ideal
or optimal. As no Hb targets between 11.3 and 13.5 g/dl were
studied, the possibility of increased risk at interim Hb values
cannot be excluded. In fact, as Hb levels below 11.3 g/dl were
not studied, the possibility remains, however unlikely, that
even the Hb target of 11.3 g/dl might be associated with
greater risk than some lower Hb target. In isolation, the
CHOIR study does not point to any specific optimal Hb
target; it simply indicates that the target should be some
value less than 13.5 g/dl. Therefore, the process of guideline
development must attempt to interpolate the results of
different Hb target studies, comparing the various Hb targets
and results to yield relative boundaries of benefit and risk.
Unfortunately, there is great overlap in target Hb levels and
substantial heterogeneity among the published studies. As a
result, it is nearly impossible to specify with any degree of
certainty what a truly optimal target Hb range should be.
Another difficulty with Hb target studies is that both the
benefit (quality of life improvement) and risk (increased
mortality rate) are affected by the Hb target selected. In
contrast, another familiar treatment decision that is a
continuous variable is target cholesterol level. The benefit
for cholesterol lowering is closely related to the achieved
cholesterol concentration, whereas the risks (liver and muscle
toxicity) are more idiosyncratic. Therefore, the cholesterol
target is more ‘one-tailed’ than Hb target, studies are easier to
design and power and results are simpler to translate into
practice guidelines. Hb target is characteristically ‘two-tailed,’
both risk and benefit are influenced by the target chosen.
Therefore, the most useful information on target Hb requires
a study in which a very large group of patients would be
randomized to multiple different Hb targets, such as
9,10,11,12, and 13 g/dl. The level at which quality of life was
maximized, whereas risk was minimized would be the optimal
target. The study would require such a large sample size that it
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would likely never occur. Without such a study, and given the
limitations of the current literature, there is insufficient
evidence for any strong Hb target recommendation.
With these cautions in mind, we shall next explore
the major treatment effects that inform the scientific
balancing of benefit and risk for Hb target; the tradeoff
of quality of life benefit against safety risk. Other factors such
as cost will not be considered in this article. The cost of ESAs
and reimbursement systems change over time and are
by their nature artificial constructs. There is great need
for formal cost benefit analyses, but this is not the purpose of
this article.
THE RELATIONSHIP OF QUALITY OF LIFE TO TARGET Hb
The World Health Organization (WHO) defines health as
‘A state of complete physical, mental, and social well-being
not merely the absence of disease’.10 WHO has developed
instruments to be used worldwide to assess health-related
quality of life (HRQOL) and assist clinicians and patients in
medical practice to improve the doctor–patient relationship,
to assess the effectiveness and relative merits of different
treatments, to be used in health service evaluation, in
research, and in policy-making.10 In its landmark publica-
tion, Crossing the Quality Chasm, the Institute of Medicine
recommended six attributes of healthcare that were needed to
optimize outcomes, including patient-centeredness – ‘provid-
ing care that is respectful of and responsive to individual
patient preferences, needs, and values and ensuring that
patient values guide all clinical decisions’.11 Patient-reported
outcomes such as HRQOL are often devalued by scientists
and clinicians, and labeled as ‘subjective’ or ‘non-rigorous’.
It is now clear, however, that HRQOL can be measured
rigorously, and available instruments can be evaluated for
reliability and validity.12 Hahn et al.12 recently have
developed a conceptual model for linking biological and
physiological variables to HRQOL. Such variables, one
example of which is the Hb level, impact symptom status,
which in turn impacts functional status. Functional status has
a major influence on general health perceptions and the latter
affect HRQOL. Considering this chain of causality, it is
remarkable that the change in any physiological variable,
such as Hb, can be shown to significantly correlate with a
change in HRQOL, but this is the case.
Quality of life of dialysis patients was dismal before the
availability of recombinant human erythropoietin. In the
phase III trials, quality of life was measured before and after
correction of anemia, from an hematocrit level typical at that
time of 22.3–35% at 12 weeks and 34% at 40 weeks.13
‘A statistically significant improvement was established
between baseline and second follow-up on most objective
and subjective quality of life parametersy’14 In a follow-up
phase IV study following FDA approval of recombinant
human erythropoietin, the quality of life impact of anemia
treatment in the general dialysis population was evaluated
using the SF-36, a validated tool to assess HRQOL.15 In
addition, aspects of QOL were compared for the dialysis
patients before and after anemia correction and individuals
in the general population as well as non-renal patients with
clinical depression or congestive heart failure. At baseline,
before receiving recombinant human erythropoietin, dialysis
patients had SF-36 scores consistently below those of the
general population as well as patients with congestive heart
failure or depression. Following partial correction of anemia
(hematocrit at baseline 25.5%, and at follow-up 29.9%),
statistically significant improvements were seen in multiple
domains of the SF-36 including physical functioning, vitality,
social functioning, mental health, mental component sum-
mary score, and percent reporting improvement in health
status over 1 year. The improvement in vitality seen was not
only statistically significant but was similar to the difference
in this domain reported between patients with chronic back
pain and the general population, and over half the
improvement in vitality observed at a 6-month follow-up
of patients who receive a new heart valve.
Although a recent meta-analysis of evidence for Hb targets
for the anemia of CKD concluded that ‘yit was not possible
to perform a pooled analysis [of quality of life studies] given
the wide variability of the assessment of these outcomes and
uncertainties regarding the validity of the instruments
usedy’, this should be viewed as a statement about statistical
methodology, not necessarily the evidence regarding Hb level
and quality of life.16 Jones et al.,17 in fact, did perform a
meta-analysis looking at quality of life impact of anemia
treatment with recombinant human erythropoietin. Sixteen
published studies were utilized for the analysis, five of which
were randomized, controlled trials. Baseline Hb was quite
low, around 8 g/dl, and quality of life at baseline, assessed
using one of several valid instruments, was low. Average Hb
increased 3.4 g/dl after treatment and significant improve-
ment in quality of life domains occurred including 15–30%
improvement from baseline in the physical and fatigue
dimensions of the instruments. When sensitivity analysis was
performed only including the randomized, controlled trials,
the results remained the same.
The real issue is not whether treatment of severe anemia in
CKD patients improves quality of life, but at what Hb level is
quality of life maximized? There is clearly conflicting data in
this regard, but a brief review of the available studies is of
some value to put this in perspective. The Canadian
Erythropoietin Study Group reported the results of a
randomized, double-masked placebo-controlled trial with
three groups: placebo (mean Hb 7.4 g/dl, n¼ 32); group 2
(mean Hb 10.2 g/dl, n¼ 34); group 3 (mean Hb 11.7 g/dl,
n¼ 33).18 Marked improvement in QOL was reported in
group 2, but no further improvement statistically in group 3.
No mention of power analysis is given here and the small
numbers of patients studied make interpretation difficult. On
the other hand, the normal hemoglobin cardiac trial
(randomized controlled trial (RCT)),19 as well as studies
from Sweden (RCT)20 and Spain,21 demonstrated quality of
life improvements in dialysis patients when Hb was targeted
at normal, compared to 10–11 g/dl. In CKD patients not yet
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on dialysis, targeting an Hb of 13.5 g/dl in the CHOIR did
not result in quality of life benefits compared to targeting an
Hb of 11.3 g/dl,7 but this finding is in marked contrast to
other recent studies. In the CREATE trial, CKD patients
randomized to a target Hb of 13–15 g/dl, compared to those
randomized to 10.5–11.5 g/dl, had significant improvements
in general health and physical function on the SF-36.8 Ritz
et al.22 reported the results of the Anemia Correction in
Diabetes (ACORD) study, involving CKD patients with
diabetes. Those randomized to a target Hb of 13–15 g/dl,
compared to 10.5–11.5 g/dl, had significantly better quality of
life as determined by SF-36. It should be noted that in the
latter two studies there were no excessive adverse events in
the high Hb groups, suggesting that on balance, benefit
(quality of life) outweighed potential harm. Finally, the use of
the SF-36 in these and many other studies is important, as it
has been shown to be highly valid and reliable.12
THE RELATIONSHIP OF SAFETY TO TARGET Hb
The benefit of ESA treatment for improving quality of life
must be balanced against the potential risk for adverse
outcomes with higher Hb targets. We will consider safety
primarily with respect to risk for mortality, as this is a highly
objective and, obviously, negatively valued outcome. Ulti-
mately, the tradeoff of quality of life benefit against risk for
mortality is the fulcrum that balances Hb target decisions for
individual patients.
Risk for mortality with various Hb targets has been the
subject of a number of observational studies. The approach is
usually to analyze a large administrative or clinical database
of end-stage renal disease patients, with collection of data on
Hb (either at a point in time or averaged over time),
outcomes, and available covariates. All observational studies
have found that there is an association between lower Hb
level and increased risk for death. From the initial work of
Lowrie and Lew, a series of studies by Collins and co-workers,
and through the recent analysis of Regidor et al., the findings
are highly consistent.23–29 In the latter study, Regidor et al.26
evaluated 58 058 subjects undergoing treatment at Da Vita
Inc. dialysis facilities. The risk for mortality increased
progressively at Hb concentrations below 12 g/dl, and the
best survival was seen when the Hb was 12–13 g/dl
(interestingly, mortality showed a trend to increase at Hb
above 13 g/dl).26
Observational research is an important scientific process
that identifies trends and relationships. The results of these
studies can never, however, define causality in relationships.
This form of research is most valuable when used to generate
hypotheses that can be tested by RCTs. The subsequent
performance of RCTs may confirm the findings of observa-
tional studies, or conversely may fail to confirm or may even
find the opposite of the observational findings. A striking
recent example of the latter is the literature on the value of
estrogen to reduce cardiovascular risk for postmenopausal
women. Observational studies consistently found estrogen to
be beneficial, and a generation of women was offered
treatment as a result. When RCTs were subsequently
performed, most notably the Women’s Health Initiative,
estrogen was found not only not to be protective, but to
actually increase risk.30 This is a dramatic example of how
observational research can mislead as to causality. As one
considers the literature on Hb target, it is becoming apparent
that for the outcome of mortality risk there are parallels to
the literature on estrogen treatment. The observational
studies indicate benefit, whereas RCTs have generally found
no benefit or even harm with higher Hb targets.
The insurmountable problem with observational research
on Hb level and mortality risk is the fact that sicker patients,
whether patients with kidney failure or with other chronic
diseases, or among individuals admitted to hospitals, tend to
have lower Hb levels.31–33 Indeed, Hb concentration tends to
decrease as illness develops and progresses.34 As a result, there
is an inherent intertwining between Hb level and health
status. Even the most sophisticated statistical methods cannot
separate the two, leaving completely unclear the question of
which causes which, between anemia and the associated
illness and health outcome. As RCTs have increasingly failed
to confirm the observational finding of a relationship
between lower Hb and increased mortality risk, the meaning
of results from the observational studies has become less
clear.
None of the published RCTs have found a significant
reduction in mortality risk with ESA treatment to higher Hb
targets. There have been eight published studies with
reasonable rigor in non-dialysis CKD7,8,35–40 and four in
hemodialysis.19,20,41,42 If all of these trials are included, then
the relative risk for mortality for the higher Hb target groups
is not significantly different than for the lower target groups;
in non-dialysis CKD relative risk is 1.01 (95% confidence
interval (CI) 0.63–1.61) and in hemodialysis it is 1.12 (95%
CI 0.91–1.37).43 However, two of the studies, with more than
500 non-dialysis patients, were stopped prematurely because
of institution of a European contraindication to subcuta-
neous administration of epoetin alfa.39,40 Importantly, the
early termination resulted in short follow-up, only 7–8
months in one study.39 In both trials, the follow-up was
probably inadequate to allow for any meaningful conclusions
on mortality risk. Without inclusion of these two studies, the
trend toward increased mortality risk is more apparent.
A recent meta-analysis reported by Phrommintikul et al.
was rigorous in terms of studies included for analysis.44 A
total of nine studies were included, four in hemodialysis, five
in non-dialysis CKD. The primary finding was a 17%
increased risk of death in patients with kidney disease treated
with ESAs to target higher Hbs (P¼ 0.03). In addition, there
were significant increases in risk for higher blood pressure
and vascular access thrombosis in the higher target groups.44
The most troubling finding from the literature is that the
three largest trials have all found substantial trends toward
increased mortality risk. The largest of these, the CHOIR
study, was a study of 1432 patients with non-dialysis CKD.
Patients were randomized to Hb targets of 11.3 and 13.5 g/dl.
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Risk for death was found to be increased in the higher Hb
target group with a hazard ratio of 1.48 and a P-value of 0.07.
The CHOIR study found a statistically significant increased
risk of a composite of death, stroke, myocardial infarction,
and hospitalization for congestive heart failure with the
higher Hb target.7
The second largest published RCT is the Normal Hemato-
crit Cardiac Trial (NHCT), a study of 1233 hemodialysis
patients. Subjects were randomized to hematocrit targets of 30
or 42%. The primary finding was a 1.21 risk ratio for death in
the higher hematocrit group. The 95% CI was 0.9–1.9,
indicating that statistical significance was nearly achieved.19
Although the study was of hemodialysis patients with cardiac
disease, the entry criteria were loose enough to apply to a
substantial proportion of the current hemodialysis population.
The third largest trial, the CREATE study, randomized 603
subjects with non-dialysis CKD to ESA treatment to target
Hb 13–15 g/dl or delayed ESA treatment to target Hb
10.5–11.5 g/dl. In this study, there was a 48% increased risk
for death, with a P-value of 0.14. In addition, there was a
trend toward increased risk based on the composite end point
in the higher Hb target group and a significantly increased
risk for reaching dialysis, as well as higher blood pressure.8
Taken together, it is remarkable that the three largest
studies, involving 3268 subjects, have had a very consistent
outcome, a 21–48% increased risk for mortality that in each
study nearly reached statistical significance.7,8,19 Each of these
studies, like all RCTs, has design flaws that can be criticized.
For example, the CHOIR study had an imbalance in baseline
cardiovascular risk characteristics and censoring of subjects
after reaching end-stage renal disease; CREATE was under-
powered because of better than anticipated cardiovascular
outcomes; and the NHCT study population may not have
been representative of the general hemodialysis population.
Future studies should take particular care to avoid such
problems, so that the interpretation of results can be made
with greater confidence. However, with the findings as
consistent as they are, it would be overly optimistic to
discard the remarkably consistent evidence due to flaws in the
individual studies. This is particularly true when the results
of these studies in kidney disease are considered together
with recent findings of increased risk for death with ESA
treatment to higher Hb targets in studies in cancer (http://
www.healthsentinel.com/news.php?id=1740&title=Studies+
Show+Anemia+Drugs+May+Harm+Cancer+Patients&event=
news_print_list_item). There is a thread of consistency
of findings that simply should not be ignored. The only
reasonable conclusion is that treatment of populations
of patients with ESAs to higher levels of Hb probably
increases the risk of death, and may adversely affect other
outcomes as well.
MECHANISM OF POTENTIAL HARM WITH HIGHER Hb
TARGETS
The major uncertainty in the current literature is the
mechanism for probable harm with achieving or targeting
of higher levels of Hb. Are there possible mechanisms of
harm related to achieved level of Hb? From the perspective of
physiology, a higher Hb results in increased blood oxygen
carriage (beneficial) and increased blood viscosity (harm-
ful).45 The normal Hb concentration in healthy individuals is
one that balances these two factors. One hypothesis for the
risk with higher Hb levels in kidney disease is that the balance
might be shifted in these patients, with increased importance
for viscosity at lower than normal Hb concentrations. Greater
viscosity results in increased sheer stress on the vascular
endothelium. In patients with pre-existing vascular disease,
and areas of vulnerable or ulcerated atherosclerotic plaque,
the effect of viscosity may be to predispose to greater risk for
thrombotic events. With the great burden of cardiovascular
disease among patients with CKD, the optimal Hb level may
be lower than for individuals without kidney disease.
A second, but related hypothesis has to do with
hemoconcentration. Anemia monitoring in hemodialysis is
somewhat unusual; in that, Hb levels are measured before the
dialysis session. As a result, Hb levels are diluted, sometimes
to a great degree. As predialysis Hb levels are used as a basis
for ESA treatment, and as Hb targets tend to be the same in
hemodialysis and non-dialysis CKD, true Hb values are
actually raised to a higher level in hemodialysis compared to
other ESA-treated populations. Furthermore, for patients
who are large weight (fluid) gainers between dialysis
treatments, a substantial amount of fluid is removed with
the hemodialysis treatment. These patients may have extreme
hemoconcentration at the end of the dialysis. It is possible
that some of the adverse outcomes in hemodialysis patients
targeted to higher Hb levels may relate to this phenomenon.
In fact, previous studies have indicated increased risk among
hemodialysis patients with larger interdialytic weight gains.46
This, of course, would not apply in non-dialysis CKD, and
would not explain the increased risk observed in the CHOIR
and CREATE studies.
A third hypothesis may be that the increased blood
pressure that may occur with raising Hb could increase
cardiovascular risk. Worsening hypertension has been an
inconsistent finding in Hb target studies, but a recent meta-
analysis found a significant increase in blood pressure in the
higher Hb target groups in these studies.44 As relatively small
changes in blood pressure could influence cardiovascular
risk, any increase could be clinically important. Attention to
blood pressure elevation during ESA treatment has probably
been insufficient.
A fourth hypothesis relates not to Hb level achieved, but
to targeting higher Hb and how this is carried out. Two of the
changes in treatment required to increase Hb include an
increase in ESA dose and increased use of iron supplementa-
tion. The increased ESA dose raises the possibility that some
aspect of ESA drug treatment other than Hb level could
potentially increase risk. ESA treatment results in serum
erythropoietin concentrations that differ greatly from the
normal biology of erythropoietin.47 In particular, serum
kinetics are notably spiky, with rapid surges in concentration
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followed by a steady decline, often to very low levels.47 The
effects of the non-biologic stimulation of erythropoietin
receptors, particularly in non-erythroid organs including the
heart, are unknown. In the heart, erythropoietin has been
demonstrated to stimulate and reset growth signals and
pathways.48 The possibility exists, and is worthy of explora-
tion, that there may be detrimental cardiac effects of excessive
and cyclical erythropoietin stimulation. A direct effect of ESA
treatment on hypertension, mediated by ESA-stimulated
effects on vascular smooth muscle cells including increases in
cytoplasmic calcium concentration, resistance to the vaso-
dilatory effects of nitric oxide, and increases in endothelin
production, has also been proposed.49 In addition, the
increase in iron treatment necessary with treatment to higher
Hb targets could also contribute to risk. Iron treatment has
been associated with increased oxidative vascular injury and
progression of atherosclerosis.50,51 Although iron use was
increased in the high hematocrit group of the Normal
Hematocrit Cardiac Trial, there was no difference in iron use
in the two groups of the CHOIR study.
THE MARCH, 2007 FDA PRESCRIBING INFORMATION
CHANGES FOR ESA DRUGS
On 9 March 2007, the US FDA acted to increase the level of
warnings for ESA drugs. The addition of a ‘black box’
warning was intended to heighten clinicians’ attention to
safety risks with these agents. Among new and intensified
warnings were the following:
K ‘Use the lowest dose of [Aranesps/EPOGENs/PRO-
CRITs] that will gradually increase the hemoglobin
concentration to the lowest level sufficient to avoid the
need for red blood cell transfusion.’
K ‘Erythropoiesis-stimulating agents (ESAs) increased
the risk for death and for serious cardiovascular events
when administered to target a hemoglobin of greater
than 12 g/dl.’
K A recommendation to withhold, not reduce ESA dose,
when Hb is greater than 12 g/dl.
REVISED NKF KDOQI ANEMIA GUIDELINES
The May, 2006 NKF KDOQI anemia guidelines contained an
evidence-based guideline recommending that Hb be main-
tained 411 g/dl in patients with CKD. In addition, there was
an opinion-based notation that there was insufficient
evidence to recommend routine ESA treatment when Hb is
greater than 13 g/dl. In early 2007, the panel reconvened to
consider the implications of a series of new studies relevant to
Hb target. As a result, the guidelines were amended in a more
conservative direction:
2.1.1. In the opinion of the work group, selection of the Hb
target and selection of the Hb level at which ESA
therapy is initiated in the individual patient should
include consideration of potential benefits (including
improvement in quality of life and avoidance of
transfusion) and potential harms (including the risk
of life-threatening adverse events) (Clinical Practice
RECOMMENDATION).
2.1.2. In the opinion of the work group, in dialysis and
non-dialysis CKD patients receiving ESA therapy, the
selected Hb target should generally be in the range of
11.0–12.0 g/dl (Clinical Practice RECOMMENDA-
TION).
2.1.3. In dialysis and non-dialysis CKD patients receiving
ESA therapy, the Hb target should not be above
13.0 g/dl (Clinical Practice GUIDELINE – MODE-
RATELY STRONG EVIDENCE).
THE TARGET Hb RANGE
The FDA prescribing instructions for ESAs and NKF KDOQI
anemia guidelines are to an extent in conflict. In this section,
we will consider the target Hb range in practice, and how to
treat within the somewhat different parameters of FDA and
KDOQI. Inevitably, the choice of Hb target range reflects the
balancing of quality of life benefit against increased risk for
mortality and other complications. Part of the dilemma is that
guideline and regulatory recommendations are based on
population management, although clinicians must treat
individual patients. As recently pointed out by Clough ‘ythe
physician is the only effective advocate for the individual
patient remaining in the health care system. When what is
good for the individual patient is in yconflict with what is
good for the population, the physician has no moral choice
but to opt for the good of the individual patienty’.52 As
discussed above, it should be clear that the current literature
does not, with any degree of certainty, define precisely the
exact boundaries of benefit or risk. Quality of life improves as
Hb is targeted to greater than 10 g/dl or even higher (a
13–15 g/dl target in the CREATE study yielded substantial
quality of life benefits). Increased risk for death probably
occurs with Hb targeted to greater than 13 g/dl. However,
there has been no demonstration that interim targets not
studied in the major trials, such as 12 or 12.5 g/dl might not
increase the risk of death. With this uncertainty, choice of Hb
target reflects the degree of risk sensitivity. A more
conservative viewpoint would be that until safety is more
clearly defined that Hb targets should be safely far from the
known boundaries of risk. A different viewpoint would be
that quality of life is such an important outcome for patients
that the Hb range should approach an upper limit of 13 g/dl.
The KDOQI recommended target range of 11–12 g/dl is a
compromise. It encourages treatment to Hb levels consistent
with demonstrated improvement in quality of life, while
avoiding targets associated with potential harm. The implied
lowering of the upper target reduces the chance of exposure to
risk at higher Hb levels but may increase the likelihood of
transient Hb levels less than 11 g/dl, with negative impact on
the quality of life benefit. The KDOQI recommendation 2.1.1
addresses this issue by promoting individualization of
treatment by considering quality of life benefit, variability in
ESA responsiveness, and the potential risk of harm in
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choosing an Hb target for individual patients. For a patient
who feels well with no decrement in quality of life, it would be
reasonable to target a lower Hb level. Conversely, for the
patient who suffers from fatigue and dyspnea, a higher target
may be justified. There may also be room for a greater
consideration of patients’ health values and preferences in
balancing quality of life against mortality risk. The KDOQI
recommended range of 11–12 g/dl does not differentiate
between hemodialysis, peritoneal dialysis, and non-dialysis
CKD. Although patient characteristics, prevalence and severity
of anemia, and treatment of anemia differ somewhat among
these different settings, the current literature is insufficient to
allow different recommendations for each.
The KDOQI generally recommended target range of
11–12 g/dl is in conflict with the FDA-revised prescribing
information for these drugs. In particular, this is true for
the FDA warning to use ESAs to raise Hb only to a level
sufficient to avoid transfusion. Clinicians differ in their views
on what Hb level indicates a need for transfusion. But few
would routinely transfuse when the Hb is greater than 10 g/dl.
This would imply that the FDA language asserts an Hb
target of only 10 g/dl. Because this level is far from the range
of demonstrated risk, and because it would deny substantial
quality of life benefits, we believe that this FDA warning is
overly cautious and potentially harmful to patients’ well being.
CONCLUSION
Availability of ESAs has improved the lives of millions of
patients with kidney disease, cancer, and other anemic states.
Treatment results in reduced need for blood transfusion and
improved quality of life. However, recent studies have
suggested potential risk for increased mortality with treat-
ment to higher Hb targets. The recent change in prescribing
information for ESA drugs, by the FDA, was an attempt to
protect patient safety in light of these studies. It is possible,
however, that the language used was excessively cautious,
potentially promoting insufficient anemia treatment with
failure to appropriately and compassionately treat fatigue and
restore compromised quality of life. During ESA treatment in
kidney disease, an Hb target of 11–12 g/dl should permit
significant quality of life improvement while avoiding the risk
associated with higher Hb targets (Figure 1).
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